AbbVie: Skyrizi And Rinvoq Latest FDA Approvals Bode Well For Humira Patent LossSeeking Alpha • 01/25/22
Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA)PRNewsWire • 01/24/22
U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic ArthritisPRNewsWire • 01/21/22
FDA Gives Back To Back Approval To Pfizer's & AbbVie's JAK Inhibitors For Atopic DermatitisBenzinga • 01/18/22
FDA Approves AbbVie's Upadacitinib For Refractory Atopic Dermatitis In Patients 12 Years & OlderBenzinga • 01/18/22
U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic DermatitisPRNewsWire • 01/14/22